Hims & Hers, a leading health care platform, has been making waves with its impressive Q4 2024 earnings report. In a recent ...

Hims & Hers expects revenue from its weight loss business to soar in 2025, even though a recent FDA move could make it ...

The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...

A series of important developments in the healthcare sector includes Medtronic adapting to tariff threats, Hims & Hers facing ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Ahead of whatever Jensen Huang & Co. announces, let's look at another highflying stock: Costco Wholesale (COST). Christopher Bloomstran, the president and chief investment officer St. Louis-based ...

Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...

Citi raised the firm’s price target on Hims & Hers to $27 from $25 and keeps a Sell rating on the shares post the Q4 report. The focus on ...